Clinical trials: Empagliflozin
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
SGLT-2 Inhibitors, Advanced Glycation End Products
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.
- Conditions
- SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
- Trial name
- NCT02768220
- Testing
- empagliflozin, linagliptin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Diabetes Mellitus, Stroke
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
Introduction: An optimal combination of antidiabetic drugs for diabetic patients with ischemic stroke is not well-established. The objective of this randomized trial is to evaluate whether combination of pioglitazone and a sodium…
- Trial name
- NCT04419337
- Testing
- Metformin plus Pioglitazone plus an SGLT2 inhibitor
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Decompensated Heart Failure
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
The pharmacokinetics (PK) and pharmacodynamics (PD) of bisoprolol and sodium-glucose co-transporter-2 inhibitors (SGLT2i, dapagliflozin and empagliflozin) in patients with acutely decompensated heart failure (ADHF), compared to…
- Trial name
- BISO-ADHF (NCT06453577)
- Testing
- Recompensation (guideline directed medical therapy)
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Universität des Saarlandes
Acute Decompensated Heart Failure (ADHF)
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared…
- Trial name
- EMPA-CON (NCT07038356)
- Testing
- Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- 12 sites in Germany
- Volunteers
- 536 people
- Sponsor
- Christian Schulze
Healthy
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and…
- Trial name
- NCT02230995
- Testing
- metformin, empagliflozin/metformin, empagliflozin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Liver Cirrhosis, Cirrhosis
Empagliflozin in Diuretic Refractory Ascites
Ascites is the most frequent complication of liver cirrhosis and results in increased morbidity and mortality but current medical management options are limited.
- Conditions
- Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic
- Trial name
- DRAin-Em 01 (NCT05013502)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Stanford University
Metabolic Syndrome, Obesity & Overweight
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
We investigate the role of empagliflozin in the treatment of obesity in PLWH.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07336797
- Testing
- Empagliflozin (oral)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Abdelrahman Mahmoud
Metabolic-associated Fatty Liver Disease, Type 2 Diabetes
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone.
- Trial name
- NCT05140694
- Testing
- Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide
- Volunteers
- 135 people
- Sponsor
- Seoul National University Bundang Hospital
Bipolar Disorder, Bipolar Depression
Empagliflozin Adjunctive Therapy in Bipolar Depression
Bipolar disorder is a long-term mental health condition that causes mood changes, with depressive episodes being the most frequent and disabling.
- Conditions
- Bipolar Disorder, Bipolar Depression, Insulin Resistance
- Trial name
- EMPA-BD (NCT07472920)
- Testing
- Empagliflozin (EMPA)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Diabetes Mellitus, Type 2
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.
- Trial name
- NCT03060980
- Testing
- ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral)
- Where
- 101 sites in United States, Canada
- Volunteers
- 245 people
- Sponsor
- Intarcia Therapeutics
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Healthy
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
To investigate the relative bioavailability of BI 10773 following coadministration with 600 mg gemfibrozil bid dosed to steady-state in comparison to BI 10773 when given alone.
- Trial name
- NCT01301742
- Testing
- BI 10773, Gemfibrozil
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dyslipidemia Associated With Type II Diabetes Mellitus
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
- Trial name
- NCT04602754
- Testing
- BERLIM 25/20 ASSOCIATION, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM
- Where
- Brazil
- Volunteers
- 228 people
- Sponsor
- EMS
Diabetes Mellitus, Type 2
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
- Trial name
- NCT00558571
- Testing
- BI 10773 low dose, BI 10773 medium dose, BI 10773 high dose
- Where
- 3 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF.
- Trial name
- EMPA-ESUS (NCT06715449)
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of East Anglia
Heart Transplant, Cardiovascular Disease
Randomized Trial of SGLT2i in Heart Transplant Recipients
Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival.
- Conditions
- Heart Transplant, Cardiovascular Disease, Kidney Disease
- Trial name
- NCT06625073
- Testing
- Empagliflozin
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07599345
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 23,955 people
- Sponsor
- Brigham and Women's Hospital
Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate
The primary aim of this clinical trial is to Evaluate the Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate.
- Conditions
- Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction
- Trial name
- NCT06641128
- Testing
- MTX SC or IM, Empagliflozin 25mg tab
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Adult Congenital Heart Disease, Heart Failure
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
- Trial name
- EmpaCHD (NCT06260059)
- Testing
- Empagliflozin 10 MG
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anita Saraf